RS50624B - Monohidrohloridna so 1-[3-[3-(4-hlorofenil)propoksi]propil]piperidina - Google Patents
Monohidrohloridna so 1-[3-[3-(4-hlorofenil)propoksi]propil]piperidinaInfo
- Publication number
- RS50624B RS50624B RSP-2008/0482A RSP20080482A RS50624B RS 50624 B RS50624 B RS 50624B RS P20080482 A RSP20080482 A RS P20080482A RS 50624 B RS50624 B RS 50624B
- Authority
- RS
- Serbia
- Prior art keywords
- chlorophenyl
- propoxy
- propyl
- piperidine monohydrochloride
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05100942A EP1690858B1 (en) | 2005-02-10 | 2005-02-10 | Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine |
| PCT/EP2006/050703 WO2006084833A1 (en) | 2005-02-10 | 2006-02-06 | Monohydrochloride salt of 1- [3- [3- (4-chlorophenyl) propoxy] propyl] -piperidine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS50624B true RS50624B (sr) | 2010-06-30 |
Family
ID=34938687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RSP-2008/0482A RS50624B (sr) | 2005-02-10 | 2006-02-06 | Monohidrohloridna so 1-[3-[3-(4-hlorofenil)propoksi]propil]piperidina |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8207197B2 (enExample) |
| EP (2) | EP1690858B1 (enExample) |
| JP (1) | JP5072604B2 (enExample) |
| KR (1) | KR101344271B1 (enExample) |
| CN (1) | CN101155793B (enExample) |
| AR (1) | AR054734A1 (enExample) |
| AT (2) | ATE391716T1 (enExample) |
| CA (1) | CA2597016C (enExample) |
| CY (1) | CY1108428T1 (enExample) |
| DE (2) | DE602005005941D1 (enExample) |
| DK (1) | DK1846384T3 (enExample) |
| ES (1) | ES2309948T3 (enExample) |
| HR (1) | HRP20080446T3 (enExample) |
| ME (1) | ME01103B (enExample) |
| MX (1) | MX2007009574A (enExample) |
| PL (1) | PL1846384T3 (enExample) |
| PT (1) | PT1846384E (enExample) |
| RS (1) | RS50624B (enExample) |
| SI (1) | SI1846384T1 (enExample) |
| TW (1) | TWI393711B (enExample) |
| UY (1) | UY29369A1 (enExample) |
| WO (1) | WO2006084833A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008157094A1 (en) * | 2007-06-13 | 2008-12-24 | Cypress Bioscience, Inc. | Improving the tolerability of mirtazapine and a second active by using them in combination |
| KR20110132564A (ko) | 2009-02-11 | 2011-12-08 | 선오비온 파마슈티컬스 인코포레이티드 | 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법 |
| RU2011153723A (ru) | 2009-06-10 | 2013-07-20 | Суновион Фармасьютикалз Инк. | Обратные агонисты и антагонисты н3 рецепторов гистамина и способы их применения |
| EP2475664A2 (en) | 2009-09-11 | 2012-07-18 | Sunovion Pharmaceuticals Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
| WO2014199935A1 (ja) * | 2013-06-10 | 2014-12-18 | 株式会社エム・エス・エス | 小胞体ストレスシグナルを抑制することによる，薬剤の副作用としての体重増加や肥満を防止するために用いられる肥満防止剤 |
| CN103435575A (zh) * | 2013-08-06 | 2013-12-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 1-（ 3-（ 3-（ 4-氯苯基）丙氧基）丙基）哌啶盐酸盐的制备方法 |
| CN104447620B (zh) * | 2014-11-28 | 2016-05-04 | 瑞阳制药有限公司 | 1-[3-[3-(4-氯苯基)丙氧基]丙基]-哌啶盐酸盐的制备方法 |
| EP3239138A1 (en) | 2016-04-25 | 2017-11-01 | Sandoz Ag | Hydrogen fumarate salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine |
| WO2020092604A1 (en) * | 2018-10-30 | 2020-05-07 | Concert Pharmaceuticals, Inc. | Deuterated pitolisant |
| IT201900013941A1 (it) | 2019-08-05 | 2021-02-05 | Procos Spa | PROCESSO PER LA SINTESI DI PITOLISANT HCl |
| CN110804026B (zh) * | 2019-11-18 | 2022-04-01 | 苏州永健生物医药有限公司 | 1- (3- (3-（4-氯苯基）丙氧基)丙基)哌啶盐酸盐的合成方法 |
| US11945788B2 (en) | 2021-06-07 | 2024-04-02 | Nuray Chemicals Private Limited | Process for preparing pitolisant hydrochloride and solid-state forms thereof |
| US11623920B2 (en) | 2021-06-07 | 2023-04-11 | Nuray Chemicals Private Limited | Process for preparing pitolisant hydrochloride and solid-state forms thereof |
| EP4457219A4 (en) * | 2021-12-29 | 2025-12-10 | Biophore India Pharmaceuticals Pvt Ltd | SOLID FORMS OF 1-3-[3-(4-CHLOROPHENYL)PROPOXY]PROPYL PIPERIDINE HYDROCHLORIDE AND THEIR PREPARATION PROCESS |
| US20250281475A1 (en) * | 2022-05-04 | 2025-09-11 | Msn Laboratories Private Limited, R & D Center | A pharmaceutical composition of pitolisant hydrochloride and their process for the preparation |
| WO2024084379A1 (en) * | 2022-10-17 | 2024-04-25 | Biophore India Pharmaceuticals Pvt. Ltd | A NOVEL PROCESS FOR THE PREPARATION OF AMORPHOUS SOLID DISPERSION OF 1-{3-[3-(4-CHLOROPHENYL) PROPOXY] PROPYL} PIPERIDINE, HYDROCHLORIDE WITH HYDROXYPROPYL BETA-CYCLODEXTRIN (HPβCD) |
| EP4374854A1 (en) | 2022-11-28 | 2024-05-29 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical mixture comprising amorphous pitolisant |
| CN121175294A (zh) | 2023-03-31 | 2025-12-19 | 生物计划制药公司 | 盐酸替洛利生的多晶型形式 |
| TW202535385A (zh) | 2023-10-16 | 2025-09-16 | 法商拜爾普羅傑特醫藥有限公司 | 必托里賽（ｐｉｔｏｌｉｓａｎｔ）之新穎調配物及使用方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0982300A3 (en) * | 1998-07-29 | 2000-03-08 | Societe Civile Bioprojet | Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications |
-
2005
- 2005-02-10 AT AT05100942T patent/ATE391716T1/de not_active IP Right Cessation
- 2005-02-10 EP EP05100942A patent/EP1690858B1/en not_active Expired - Lifetime
- 2005-02-10 DE DE602005005941T patent/DE602005005941D1/de not_active Expired - Lifetime
-
2006
- 2006-02-06 CN CN200680008857.1A patent/CN101155793B/zh active Active
- 2006-02-06 PL PL06708050T patent/PL1846384T3/pl unknown
- 2006-02-06 MX MX2007009574A patent/MX2007009574A/es active IP Right Grant
- 2006-02-06 ME MEP-2008-394A patent/ME01103B/me unknown
- 2006-02-06 CA CA2597016A patent/CA2597016C/en active Active
- 2006-02-06 HR HR20080446T patent/HRP20080446T3/xx unknown
- 2006-02-06 DE DE602006001938T patent/DE602006001938D1/de active Active
- 2006-02-06 US US11/815,736 patent/US8207197B2/en active Active
- 2006-02-06 AT AT06708050T patent/ATE402154T1/de active
- 2006-02-06 EP EP06708050A patent/EP1846384B1/en active Active
- 2006-02-06 ES ES06708050T patent/ES2309948T3/es active Active
- 2006-02-06 RS RSP-2008/0482A patent/RS50624B/sr unknown
- 2006-02-06 DK DK06708050T patent/DK1846384T3/da active
- 2006-02-06 PT PT06708050T patent/PT1846384E/pt unknown
- 2006-02-06 SI SI200630073T patent/SI1846384T1/sl unknown
- 2006-02-06 WO PCT/EP2006/050703 patent/WO2006084833A1/en not_active Ceased
- 2006-02-06 JP JP2007554541A patent/JP5072604B2/ja active Active
- 2006-02-08 AR ARP060100448A patent/AR054734A1/es not_active Application Discontinuation
- 2006-02-08 TW TW095104184A patent/TWI393711B/zh active
- 2006-02-09 UY UY29369A patent/UY29369A1/es not_active Application Discontinuation
-
2007
- 2007-09-06 KR KR1020077020422A patent/KR101344271B1/ko active Active
-
2008
- 2008-10-21 CY CY20081101174T patent/CY1108428T1/el unknown
-
2012
- 2012-06-07 US US13/491,229 patent/US8354430B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS50624B (sr) | Monohidrohloridna so 1-[3-[3-(4-hlorofenil)propoksi]propil]piperidina | |
| DK2038268T3 (en) | Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands | |
| EP3487839B1 (en) | Amide derivatives as nav1.7 and nav1.8 blockers | |
| US20080188524A1 (en) | Methods of treating pain | |
| RU2731095C2 (ru) | Производное 5-этил-4-метил-пиразол-3-карбоксамида, обладающее активностью агониста taar | |
| EP1286670A2 (en) | Use of therapeutic benzamide derivatives | |
| WO2009132454A1 (en) | Di-t-butylphenyl piperazines as calcium channel blockers | |
| KR101802726B1 (ko) | 오렉신 수용체 안타고니스트로서의 프롤린 술폰아미드 유도체 | |
| KR20160093683A (ko) | 오렉신 수용체 길항제로서의 (ｓ)-(２-(６-클로로-７-메틸-１ｈ-벤조[ｄ]이미다졸-２-일)-２-메틸피롤리딘-１-일)(５-메톡시-２-(２ｈ-１,２,３-트리아졸-２-일)페닐)메타논의 결정성 염 형태 | |
| WO2024124056A1 (en) | Novel sulfoximine activators of serotonin receptors | |
| EP2681209B1 (en) | Compounds and methods for the treatment of pain and other disorders | |
| JP2010507589A (ja) | Ｃｂｌ’受容体モジュレーターとしての１，５−ジフェニル−３−ピリジニルアミノ−１，５−ジヒドロピロリジン−２−オン | |
| US20220008414A1 (en) | Pharmaceutical composition comprising histone deacetylase 6 inhibitors | |
| JPH037257A (ja) | ピリジン誘導体及びそれを有効成分とする向精神剤 | |
| JP7200258B2 (ja) | デュアルの５－ｈｔ２ａおよび５－ｈｔ６受容体アンタゴニストとしての新しいインドールおよびベンゾイミダゾール誘導体 | |
| DE102004006808A1 (de) | Substituierte 4,5,6,7-Tetrahydro-benzothiazol-2-ylamin-Verbindungen | |
| WO2004089922A2 (en) | Calcium channel inhibitors comprising benzhydril spaced from piperazine | |
| EP1611116A2 (en) | Calcium channel inhibitors comprising benzhydril spaced from piperazine | |
| HK1138566B (en) | Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators | |
| HK1138566A1 (en) | Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators |